Scientists seek best dose of Last-Resort antibiotics for superbug infections

NCT ID NCT06717594

Recruiting now Knowledge-focused Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study is looking at how two antibiotics, ceftazidime/avibactam and fosfomycin, work in the body to treat infections caused by carbapenem-resistant Enterobacterales (CRE), a type of superbug. Researchers will monitor 60 adult patients to see if the drug levels in their blood reach targets that effectively kill the bacteria. The goal is to find the right dosing to improve treatment for these difficult infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftazidime/avibactam and fosfomycin
What this could lead to: If successful, this study could help doctors determine the most effective dosing of these antibiotics for treating hard-to-kill CRE infections.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. The small size (60 participants) and focus on specific bacteria may limit how widely the results apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIMICROBIAL RESISTANCE (AMR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIMICROBIAL RESISTANCE (AMR) GRAM NEGATIVE INFECTIONS

Contacts and locations

Locations

IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITING

Bologna, Bologna, 40138, Italy
Instituto de Biomedicina de Sevilla (IBiS), Hospital Virgen Macarena/CSIC/Universidad de Sevilla
RECRUITING

Seville, Seville, 41013, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.